Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q2 2024 · 10-Q
Revenue$140.00K$140.00K−13.0% vs Q2 2023 Net Income-$1.27M-$1.27MN/M vs Q2 2023 EPS Diluted-$5.37-$5.37N/M vs Q2 2023 Gross Profit$30,000−50.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,287,000N/M Margins · derivedGross margin21.4%−16.5 pt vs Q2 2023
Operating margin-904.3%+415.6 pt vs Q2 2023
Net margin-904.3%+415.6 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end